SCHEMBL8926474

SCHEMBL8926474

C#CCCCCCCCCCOc1ccc(C=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
LMNA P02545 3/20 0.53
MAPT P10636 3/20 0.53
HPGD P15428 2/20 0.53
MAOB P27338 8/20 0.47
MAOA P21397 4/20 0.47
KDM4E B2RXH2 3/20 0.46
CA12 O43570 1/20 0.41
CA9 Q16790 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
CYP2A6 P11509 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
ALOX5 P09917 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1232335 0.98 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL3346351 0.93 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
Hydrochloric Acid SCHEMBL28530836 0.92 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL11912907 0.88 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL8315263 0.86 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL3113016 0.86 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL8373486 0.86 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL8374769 0.86 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL8373505 0.86 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2LMNAMAPTHPGD
SCHEMBL8549614 0.86 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2LMNAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9920014-B2 Selective inhibition of bacterial topoisomerase I THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2018-03-20 US disclosed
US-20160229810-A1 Selective Inhibition of Bacterial Topoisomerase I THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2016-08-11 US disclosed
WO-2015042438-A1 SELECTIVE INHIBITION OF BACTERIAL TOPOISOMERASE I THE FLORIDA INTERNATIONAL BOARD OF TRUSTEES MODESTO A. MAIDIQUE CAMPUS (US) 2015-03-26 WO disclosed
US-5663042-A LIGHT AND HEAT SENSITIVE SILVER HALIDE ELEMENNTS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-09-02 US disclosed
EP-0681210-A1 Novel developing agents for (photo) thermographic systems MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229810-A1 Selective Inhibition of Bacterial Topoisomerase I TOP1, TOP2B, TOP2A ALDH1A1 3784/4885SMN1; SMN2 4650/4885LMNA 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.